TABLE 3.
Logistic regression analysis of the associated factors of biosimilar uptake (n = 446).
| Variables | Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) | p-value | OR (95%CI) | p-value | Β (95%CI) | p-value | ||||
| Patient’s age | 1.04(1.01–1.07) | <0.01 | 1.03(1.01–1.06) | 0.02 | .12(.04–.20) | <0.01 | |||
| Tumor stage (Ref. I ∼ II) | |||||||||
| III | .85(.42–1.71) | 0.64 | .87(.42–1.81) | 0.71 | −.14(-.87–.59) | 0.72 | |||
| IV | 1.73(.95–3.14) | 0.07 | 1.78(.95–3.34) | 0.07 | .55(-.09–1.18) | 0.09 | |||
| Type of health insurance coverage (Ref. urban employee program) | |||||||||
| urban and rural resident program | 1.93(1.11–3.33) | 0.02 | 1.87(1.06–3.29) | 0.03 | .67(.10–1.24) | 0.02 | |||
| others | 1.74(.16–18.7) | 0.65 | 2.18(.17–28.3) | 0.56 | 1.06(-1.53–3.65) | .42 | |||
| Whether treatment with trastuzumab was initiated before January 2021 (Ref. no) | |||||||||
| yes | .41(.16–1.03) | 0.06 | .36(.14–.95) | 0.04 | −1.04(-2.00∼-.09) | 0.03 | |||
| Physician’s age | .91(.86–.97) | <0.01 | −.09(-.15∼-.04) | <0.01 | |||||
| Physician’s gender (Ref. male) | |||||||||
| female | 2.30(1.31–4.02) | <0.01 | .84(.28–1.40) | <0.01 | |||||
| Physician’s academic rank (Ref. deputy chief physician) | |||||||||
| chief physician | 4.35(2.01–9.39) | <0.01 | 1.73(.85–2.61) | <0.01 | |||||
| The interaction term of patients’ age and physicians’ academic rank | −.10(-.19∼-.01) | 0.03 | |||||||